{"denoms":[{"counts":[{"groupId":"BG000","value":"19"}],"units":"Participants"}],"groups":[{"description":"CONDITIONING: Patients receive busulfan IV over 3 hours on days -6 to -3, melphalan IV over 20 minutes on day -2, and bortezomib IV over 3-5 seconds on days -6, -3, 1, and 4.\n\nTRANSPLANT: Patients undergo autologous PBSCT on day 0.\n\nBusulfan: Given IV\n\nMelphalan: Given IV\n\nBortezomib: Given IV\n\nAutologous Hematopoietic Stem Cell Transplantation: Undergo autologous PBSCT\n\nPeripheral Blood Stem Cell Transplantation: Undergo autologous PBSCT","id":"BG000","title":"Treatment (Busulfan, Melphalan, Bortezomib, Autologous PBSCT)"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"32","upperLimit":"70","value":"55"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"19"}],"units":"Participants"}]}],"dispersionType":"INTER_QUARTILE_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"6"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"13"}],"title":"Male"}],"denoms":[{"counts":[{"groupId":"BG000","value":"19"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"denoms":[{"counts":[{"groupId":"BG000","value":"0"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Race and Ethnicity were not collected from any participant.","title":"Race and Ethnicity Not Collected","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"4"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"19"}],"units":"Participants"}],"title":"Stage 1"},{"categories":[{"measurements":[{"groupId":"BG000","value":"7"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"19"}],"units":"Participants"}],"title":"Stage 2"},{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"19"}],"units":"Participants"}],"title":"Stage 3"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"19"}],"units":"Participants"}],"title":"Stage unkown"}],"description":"The international staging system (ISS) was used to stage the patients.\n\n* Stage I: Serum beta-2 microglobulin \\< 3.5 mg/L and serum albumin ≥3.5 g/dL - Good outcome\n* Stage II: Not stage I or stage III - Slightly worse outcome\n* Stage III: Serum beta-2 microglobulin ≥ 5.5 mg/L - Worse outcome\n\nFor 16 of them ISS was available at initial diagnosis.","paramType":"NUMBER","title":"ISS stage at diagnosis","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"19"}],"units":"Participants"}],"title":"High risk"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"19"}],"units":"Participants"}],"title":"Intermediate risk"},{"categories":[{"measurements":[{"groupId":"BG000","value":"6"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"19"}],"units":"Participants"}],"title":"Standard risk"},{"categories":[{"measurements":[{"groupId":"BG000","value":"10"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"19"}],"units":"Participants"}],"title":"Unknown"}],"paramType":"NUMBER","title":"Cytogenetics/FISH at diagnosis","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"17"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"19"}],"units":"Participants"}],"title":"Bortezomib-containing regimen"},{"categories":[{"measurements":[{"groupId":"BG000","value":"7"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"19"}],"units":"Participants"}],"title":"Immunomodulatory agent-containing regimen"}],"paramType":"NUMBER","title":"Previous treatment","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"19"}],"units":"Participants"}],"title":"Complete response"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"19"}],"units":"Participants"}],"title":"Very Good partial response"},{"categories":[{"measurements":[{"groupId":"BG000","value":"10"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"19"}],"units":"Participants"}],"title":"Partial response"},{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"19"}],"units":"Participants"}],"title":"Stable disease"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"19"}],"units":"Participants"}],"title":"Progressive disease"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Response before ASCT","unitOfMeasure":"Participants"}]}